Lupin Limited and Astellas Pharma Patent Dispute Settlement

Lupin Limited has settled its patent dispute with Astellas Pharma over the generic version of Mirabegron in a $90 million agreement. The February 2026 settlement resolves U.S. infringement litigation and allows Lupin to continue selling the drug through September 2027. The deal includes a $75 million upfront payment and additional per-unit licensing fees, securing Lupin’s market presence while ending a high-stakes legal battle in the United States.

https://analystip.com/lupin-an....d-astellas-patent-di